Argenica Therapeutics Advances Stroke Trial Progress

Argenica Therapeutics Ltd (AU:AGN) has released an update.

Argenica Therapeutics is making significant progress in its Phase 2 trial for acute ischaemic stroke, having dosed 80% of its target patients. The trial, which is on track to complete by mid-2025, is showing positive feedback with no reported issues. Argenica is also preparing to submit an Investigational New Drug application to the FDA, paving the way for future trials in the U.S.

For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.